6Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents. Vol. VIII. IARC Scientific Publication No. 155. Lyon: IARC, 2002: 745-747.
7Curado MP, Edwards B, Shin HR, et al. Cancer incidence in five continents. Vol. IX. IARC Scientific Publication No. 160. Lyon: IARC, 2008.
8Jensen OM, Parkin DM, MacLennan R, et al. Cancer registration: principles and methods. IARC Scientific Publication No. 95. Lyon.. IARC, 1991.. 101-107.
9Parkin DM, Chen VW, Ferlay J, et al. Comparability and quality control in cancer registration. IARC Technical Report No. 19. Lyon.. IARC, 1994: 35-49.
10Felay J, Burkhard C, Whelan S, et al. Check and conversion programs for cancer registries. IARC Technical Report No. 42. Lyon: IARC, 2005: 11-38.
3Jemal A,Murray T,Ward E,et al.Cancer statistics,2005[J].CA Cancer J Clin,2005,55(1):10-30.
4Ferlay J,Shin HR,Bray F,et al.Estimates of worldwideburden of cancer in 2008:GLOBOCAN 2008[J].Int JCancer,2010,127(12):2893-28917.
5Li Y,McCadden J,Ferrer F,et al.Prostate-specific ex-pression of the diphtheria toxin A chain(DT-A):studiesof inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-media-ted gene transfer[J].Cancer Res,2002,62(9):2576-2582.
6Jemal A,Siegel R,Ward E,et al.Cancer statistics,2006[J].CA Cancer J Clin,2006,56(2):106-130.
7Green DR,Reed JC.Mitochondria and apoptosis[J].Science,1998,281(5381):1309-1312.
8Jemal A,Murray T,Ward E,et al.Cancer statistics,2005[J]. CA Cancer J Clin,2005,55(1):10-30.
9Rouvière O,Glas L,Girouin N,et al.Prostate cancerablation with transrectal high-intensity focused ultra-sound:assessment of tissue destruction with contrast-en-hanced US[J].Radiology,2011,259(2):583-91.
10Chi KN,Chin JL,Winquist E,et al.Multicenter phase IIstudy of combined neoadjuvant docetaxel and hormonetherapy before radical prostatectomy for patients withhigh risk localized prostate cancer[J].J Urol,2008,180(2):565-570.
